Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000899140-12-000462
Filing Date
2012-07-03
Accepted
2012-07-03 16:31:52
Documents
2
Group Members
CHARLES R. KAYEJOSEPH P. LANDYWARBURG PINCUS & CO.WARBURG PINCUS LLCWARBURG PINCUS PARTNERS LLCWARBURG PINCUS X L.P.WARBURG PINCUS X LLCWARBURG PINCUS X PARTNERS L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 w8015835.htm SC 13D/A 258686
2 AMENDMENT NO. 1 TO THE INVESTMENT AGREEMENT w8015835b.htm EX-99.12 49746
  Complete submission text file 0000899140-12-000462.txt   310508
Mailing Address 2207 BRIDGEPOINTE PARKWAY SUITE 250 SAN MATEO CA 94404
Business Address 2207 BRIDGEPOINTE PARKWAY SUITE 250 SAN MATEO CA 94404 650-588-6404
Talon Therapeutics, Inc. (Subject) CIK: 0001140028 (see all company filings)

EIN.: 320064979 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-79910 | Film No.: 12945486
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Business Address C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 212-878-0600
Warburg Pincus Private Equity X, L.P. (Filed by) CIK: 0001414565 (see all company filings)

EIN.: 260849130 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A